Share This Article:

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

Abstract Full-Text HTML Download Download as PDF (Size:562KB) PP. 1298-1305
DOI: 10.4236/jct.2013.48153    4,320 Downloads   9,279 Views  

ABSTRACT


Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were evaluated. From 2000 to 2007, 134 consecutive DLBCL patients are qualified for the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630 cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced inferior overall survival (OS) and progression free survival (PFS). On multivariate analysis, the AMC-100 and ALC-100 remained independent predictors of OS and PFS. Combining both values into the AMLPS-100, the 5-year OS rates for low, intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% - 98.1%), 70% (95% CI, 58.6% - 80.1%), and 13% (95% CI, 3.4% - 40.5%), respectively; and the 5-year PFS rates were 87% (95% CI, 74.0% - 94.1%), 68% (95% CI, 56.0% - 77.8%), and 13% (95% CI, 3.4% - 40.5%), respectively. The AMLPS-100 is a simple biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT in DLBCL patients.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Velazquez, D. Inwards, S. Ansell, I. Micallef, P. Johnston, W. Hogan, S. Markovic and L. Porrata, "Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma," Journal of Cancer Therapy, Vol. 4 No. 8, 2013, pp. 1298-1305. doi: 10.4236/jct.2013.48153.

References

[1] L. J. DeCook, M. Thoma, T. Huneke, N. D. Johnson, R. A., M. M. Patnaik, et al., “Impact of Lymphocyte and Monocyte Recovery on the Outcomes of Allogeneic Hematopoietic SCT with Fludarabine and Melphalan Conditioning,” Bone Marrow Transplantation, Vol. 48, No. 5, 2013, pp. 708-714.
http://dx.doi.org/10.1038/bmt.2012.211
[2] B. Bolwell, B. Pohlman, R. Sobecks, S. Andresen, S. Brown, L. Rybicki, et al., “ Prognostic Importance of the Platelet Count 100 Days Post Allogeneic Bone Marrow Transplant,” Bone Marrow Transplantation, Vol. 33, No. 4, 2004, pp. 419-423. http://dx.doi.org/10.1038/sj.bmt.1704330
[3] Z. Kuzmina, S. Eder, A Bohm, E. Pernicka, L. Vormittag, P. Kahs, et al., “Significant Worse Survival of Patients with NIH-Defined Chronic Graft-versus-Host Disease and Thrombocytopenia or Progressive Onset Type: Results of a Prospective Study,” Leukemia, Vol. 26, No. 4, 2012, pp. 746-756.
http://dx.doi.org/10.1038/leu.2011.257
[4] S. G. Holtan, W. J. Hogan, M. A. Elliott, S. M. Ansell, D. J. Inwards, L. F. Porrata, et al., “CD34+ Cell Dose and Establishment of Full Donor Chimerism at Day +100 Are Important Factors for Survival with Reduced-Intensity Conditioning with Fludarabine and Melphalan before Allogeneic Hematopoietic SCT for Hematologic Malignancies,” Bone Marrow Transplantation, Vol. 45, No. 12, 2010, pp. 1699-1703. http://dx.doi.org/10.1038/bmt.2010.49
[5] R. A. Wilcox, K. Ristow, T. M. Habermann, D. J. Inwards, I. N. M. Micallef, P. B. Johnston, et al., “The Absolute Monocyte and Lymphocyte Prognostic Score Predicts Survival and Identifies High-Risk Patients in Diffuse Large-B-Cell Lymphoma,” Leukemia, Vol. 25, No. 9, 2011, pp. 1502-1509.
http://dx.doi.org/10.1038/leu.2011.112
[6] N. Batty, E. Ghonimi, L. Feng, L. Fayad, A. Younes, M. A. Rodriguez, et al., “The Absolute Monocyte and Lymphocyte Prognostic Index for Patients with Diffuse Large-B-Cell Lymphoma Who Receive R-CHOP,” Clinical Lymphoma, Myeloma & Leukemia, Vol. 13, No. 1, 2013, pp. 15-18.
http://dx.doi.org/10.1016/j.clml.2012.09.009
[7] C. Keane, D. Gill, F. Vari, D. Cross, L. Griffiths and M. Gandhi, “CD4 Tumor Infiltrating Lymphocytes Are Prognostic and Independent of R-IPI in Patients with DLBCL Receiving R-CHOP Chemo-Immunotherapy,” American Journal of Hematology, Vol. 88, No. 4, 2013, pp. 273-276.
http://dx.doi.org/10.1002/ajh.23398
[8] D. K. Hiwase, S. Hiwase, M. Bailey, G. Bollard and A. P. Schwarer, “Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma,” Biology of Blood and Marrow Transplantation, Vol. 14, No. 7, 2008, pp. 116-124.
http://dx.doi.org/10.1016/j.bbmt.2007.08.051
[9] L. F. Porrata, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston, D. A. Gastineau, et al., “Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study,” Biology of Blood and Marrow Transplantation, Vol. 14, No. 7, 2008, pp. 807-816. http://dx.doi.org/10.1016/j.bbmt.2008.04.013
[10] D. G. Stover, V. K. Reddy, Y. Shyr, B. N. Savani and N. Reddy, “Long-Term Impact of Prior Rituximab Therapy and Early Lymphocyte Recovery on Auto-SCT Outcome for Diffuse Large B-Cell Lymphoma,” Bone Marrow Transplantation, Vol. 47, No. 1, 2012, pp. 82-87.
http://dx.doi.org/10.1038/bmt.2011.29
[11] L. F. Porrata, M. A. Gertz, D. J. Inwards, M. R. Litzow, M. Q. Lacy, A. Tefferi, et al., “Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma or Non-Hodgkin Lymphoma,” Blood, Vol. 98, No. 3, 2001, pp. 579-585.
http://dx.doi.org/10.1182/blood.V98.3.579
[12] M. R. Boulassel, A. L. Herr, M. D. DebEdwards, A. Galal, S. Lachance, P. Laneuville, et al., “Early Lymphocyte Recovery Following Autologous Peripheral Stem Cell Transplantation Is Associated with Better Survival in Younger Patients with Lymphoproliferative Disorders,” Hematology, Vol. 11, No. 3, 2006, pp. 165-170. http://dx.doi.org/10.1080/10245330600667559
[13] L. N. Gordan, M. W. Sugrue, J. W. Lynch, K. D. Williams, S. A. Khan and J. S. Moreb, “Correlation of Early Lymphocyte Recovery and Progression-Free Survival after Autologous Stem-Cell Transplant in Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma,” Bone Marrow Transplantation, Vol. 31, No. 11, 2003, pp. 1009-1013. http://dx.doi.org/10.1038/sj.bmt.1704050
[14] C. Joao, L. F. Porrata, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston, et al., “Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle-Cell Lymphoma,” Bone Marrow Transplantation, Vol. 37, No. 9, 2006, pp. 865-871.
http://dx.doi.org/10.1038/sj.bmt.1705342
[15] H. Kim, H. J. Sohn, S. Kim, J. S. Lee, W. K. Kim and C. Suh, “Early Lymphocyte Recovery Predicts Longer Survival after Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma,” Bone Marrow Transplantation, Vol. 37, No. 11, 2006, pp. 1037-1042.
http://dx.doi.org/10.1038/sj.bmt.1705373
[16] H. Kim, H. J. Sohn, S. E. Kim, H. J. Kang, S. Park, S. Kim, et al., “Lymphocyte Recovery Prolonged Survival after Autologous Peripheral Blood Stem Cell Transplantation in T-Cell Non-Hodgkin’s Lymphoma,” Bone Marrow Transplantation, Vol. 34, No. 1, 2004, pp. 43-49.
http://dx.doi.org/10.1038/sj.bmt.1704530
[17] L. F. Porrata, M. A. Gertz, M. R. Litzow, M. Q Lacy, A. Dispenzieri, D. J. Inwards, et al., “Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis,” Clinical Cancer Research, Vol. 11, 2005, pp. 1120-1218.
[18] L. F. Porrata, D. J. Inwards, I. N. Micallef, S. M. Ansell, S. M. Geyer and S. N. Markovic, “Early Lymphocyte Recovery Post-Autologous Haematopoietic Stem Cell Transplantation Is Associated with Better Survival in Hodgkin’s Disease,” British Journal of Haematology, Vol. 117, No. 3, 2006, pp. 629-633. http://dx.doi.org/10.1046/j.1365-2141.2002.03478.x
[19] L. F. Porrata, M. R. Litzow, A. Tefferi, L. Letendre, S. Kumar, S. M. Gever, et al., “Early Lymphocyte Recovery Is a Predictive Factor for Prolonged Survival after Autologous Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia,” Leukemia, Vol. 16, No. 7, 2002, pp. 1311-1318. http://dx.doi.org/10.1038/sj.leu.2402503
[20] G. Ferrandina, L. Pierelli, A. Perillo, S. Rutela, M. Ludovisi, G. Leone, et al., “Lymphocyte Recovery in Advanced Ovarian Cancer Patients after High-Dose Chemotherapy and Peripheral Blood Stem Cell Plus Growth Factor Support: Clinical Implications,” Clinical Cancer Research, Vol. 9, 2003, pp. 195-200.
[21] Y. Nieto, E. J. Shpall, I. K. McNiece, S. Nawaz, J. Beaudet, S. Rosinki, et al., “Prognostic Analysis Of Early Lymphocyte Recovery in Patients with Advanced Breast Cancer Receiving High-Dose Chemotherapy with an Autologous Hematopoietic Progenitor Cell Transplant,” Clinical Cancer Research, Vol. 10, 2004, pp. 5076-5086.
[22] L. F. Porrata, J. N. Ingle, M. R. Litzow, S, Geyer and S. N. Markovic, “Prolonged Survival Associated with Early Lymphocyte Recovery after Autologous Hematopoietic Stem Cell Transplantation for Patients with Metastatic Breast Cancer,” Bone Marrow Transplantation, Vol. 28, No. 9, 2001, pp. 865-871. http://dx.doi.org/10.1038/sj.bmt.1703236
[23] B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 5, 2007, pp. 579-586. http://dx.doi.org/10.1200/JCO.2006.09.2403
[24] E. L. Kaplan and P. Meier, “Nonparametric Estimation from Incomplete Observations,” Journal of the American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481.
http://dx.doi.org/10.1080/01621459.1958.10501452
[25] D. Cox, “Regression Models and Life Tables,” Journal of the Royal Statistical Society B, Vol. 34, 1972, pp. 187-202.
[26] C. M. Diaz-Montero, M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole and A. J. Montero, “Increased Circulating Myeloid-Derived Suppressor Cells Correlate with Clinical Cancer Stage, Metastatic Tumor Burden, and Doxorubicin-Cyclophosphamide Chemotherapy,” Cancer Immunology, Immunotherapy: CII, Vol. 58, 2009, pp. 49-59.
[27] D. I. Gabrilovich and S. Nagaraj, “Myeloid-Derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology, Vol. 9, 2009, pp. 162-174.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.